Company / Current Assets
Jade Biosciences, Inc. Current Assets History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$80.1M
FY2024
5-year range
$4.7M / $174.3M
FY2020-FY2024
Trend
-35.5%
vs FY2023
Sector context
#207 of 214
Health Care
What the data says
Among 214 Health Care companies, Jade Biosciences, Inc. is in the bottom 3% for current assets. Current Assets has declined for 3 consecutive years, from $174M in FY2021 to $80M in FY2024.
Based on SEC 10-K filings.
$80M in FY2024 with a 3-year CAGR of -22.8%.
Declined from $131M to $80M over the past 2 years.
Health Care sector context is included.
Current Assets over time
Growth rates
- 3-Year CAGR
- -22.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 3% in Health CareTop 97% of 214This company $80.1M Sector average $2.5B
▼
-96.8% below sector average
Key checks
Key Insights
- Jade Biosciences, Inc.'s current assets has declined for 3 consecutive years.
- 3-year CAGR of -22.8%, indicating a declining trend.
- In FY2024, current assets decreased 35.5% year-over-year.
- Ranks #207 out of 214 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.03 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $80.1M | -35.5% |
| FY2023 | $124.2M | -5.5% |
| FY2022 | $131.5M | -24.6% |
| FY2021 | $174.3M | +3628.3% |
| FY2020 | $4.7M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026